A British Lung Foundation (BLF) report based on a landmark survey found that more than three-quarters of chronic…
Mary Chapman
Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Mary Chapman
A new wearable device can remotely assess lung function in patients and, if federally approved, may help with the early…
Sporting the color orange and “lacing up” for patients, supporters nationwide are participating in COPD Awareness Month, observed each November…
NuvoAir announced it has raised $12 million in Series A funding, which it will use to expand a digital care…
Two Montreal-based foundations are joining forces to boost research and care into complex and chronic respiratory disorders, including chronic…
To help people experiencing the lingering effects of coronavirus infection, the Pulmonary Wellness Foundation (PWF) has launched a…
November is National Chronic Obstructive Pulmonary Disease (COPD) Awareness Month, and to recognize it and the people with this…
A new national report from the Ontario Lung Association (OLA) highlights significant knowledge gaps about chronic obstructive pulmonary…
Priority Health will cover Pulmonx’s Zephyr Endobronchial Valve device as a non-surgical treatment option for severe emphysema, a severe form…
Kali-Extracts has launched a dedicated website for its cannabis-based therapy candidate, RespRX, for chronic obstructive pulmonary disease…